Indisulam Explained

Indisulam is a chloroindolyl sulfonamide cell cycle inhibitor that exhibits antitumor activity in vitro and in an animal model.^{[1] [2] [3]} This compound affects cell cycle progression in human tumor cells and is being studied for the treatment of cancers such as melanomas and blood-borne cancers such as leukemia.^[4]

Notes and References

1. Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells. Fukuoka K, Usuda J, Iwamoto Y, etal . Invest New Drugs. 19. 2001 . 3. 219–27. 10.1023/A:1010608317361. 11561678. 26100991.
2. E7070, a Novel Sulphonamide Agent With Potent Antitumour Activity in Vitro and in Vivo . Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K . November 2001 . 11677118 . European Journal of Cancer . 37 . 17 . 2275–82 . 10.1016/s0959-8049(01)00275-1 .
3. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer . E. Raymond . W.W. ten Bokkel Huinink . J. Taïeb . J.H. Beijnen . S. Faivre . J. WandersM. Ravic . P. Fumoleau . J.P. Armand . J.H.M. Schellens . 2002-08-15 . 12177112 . Journal of Clinical Oncology . 20 . 16 . 3508–21 . 10.1200/JCO.2002.09.030 .
4. Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood. 130. supplement 1. 2001 . Rita Assi . Hagop M. Kantarjian . Jorge E. Cortes . Tapan Kadia . Naveen Pemmaraju . Elias J. Jabbour . Nitin Jain . Naval Daver . Taisuke Uehara . Takashi Owa . Gautam Borthakur.